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 2
SUMMARY 25 
Many membrane proteins fold inefficiently and require the help of enzymes and chaperones. 26 
Here we reveal a novel folding assistance system that operates on membrane proteins from the 27 
cytosolic side of the endoplasmic reticulum (ER). We show that folding of the Wnt signaling 28 
coreceptor LRP6 is promoted by ubiquitination of a specific lysine, retaining it in the ER 29 
while avoiding degradation. Subsequent ER exit requires removal of ubiquitin from this lysine 30 
by the deubiquitinating enzyme USP19. This ubiquitination-deubiquitination is conceptually 31 
reminiscent of the glucosylation-deglucosylation occurring in the ER lumen during the 32 
calnexin/calreticulin folding cycle. To avoid infinite futile cycles, folded LRP6 molecules 33 
undergo palmitoylation and ER export, while unsuccessfully folded proteins are, with time, 34 
polyubiquitinated on other lysines and targeted to degradation. This ubiquitin-dependent 35 
folding system also controls the proteostasis of other membrane proteins as CFTR and anthrax 36 
toxin receptor 2, two poor folders involved in severe human diseases.  37 
 38 
  39 
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INTRODUCTION 40 
While protein folding may be extremely efficient, the presence of multiple domains, in soluble 41 
or membrane proteins, greatly reduces the efficacy of the overall process. Thus, a set of 42 
enzymes and chaperones assist folding and ensure that a sufficient number of active molecules 43 
reach their final destination (Brodsky and Skach, 2011; Ellgaard et al., 2016). Even with help, 44 
folding may remain inefficient and thereby sensitive to errors or mutations, leading to disease. 45 
An illustrative example of folding inefficiency, and the consequences thereof, is the Cystic 46 
Fibrosis Transmembrane Regulator (CFTR), a chloride channel expressed at the surface of 47 
lung epithelial cells (Riordan, 2008). It has been estimated that less than 25% of newly 48 
synthesized CFTR molecules actually reach the plasma membrane. When the number of 49 
functional CFTR channels is further reduced, patients suffer from Cystic Fibrosis (Riordan, 50 
2008). This is the case for mutations that affect the kinetics or thermodynamics of CFTR 51 
folding in the ER, such as the most frequent CF mutation ΔF508, and which are recognized by 52 
ER quality control systems and targeted for degradation (Riordan, 2008). 53 
Inefficiency in folding is a fairly common characteristic of transmembrane proteins (Abrami et 54 
al., 2008b; Deuquet et al., 2009; Guerriero and Brodsky, 2012). Most transmembrane proteins, 55 
which jointly compose 30% of the human proteome, are synthesized by ER-bound ribosomes 56 
and co-translationally inserted into the ER membrane (Ellgaard et al., 2016; Xu and Ng, 57 
2015). Subsequent folding must proceed in three topological environments: the ER lumen, the 58 
membrane and the cytosol. In each of these environments, the protein may benefit from the 59 
help of chaperones and folding enzymes. On the luminal side, these are fairly well 60 
characterized and include HSP40, HSP70 and HSP90 family members (Brodsky and Skach, 61 
2011), the lectin chaperones calnexin and calreticulin (Lamriben et al., 2016) and protein 62 
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disulfide isomerases (Brodsky and Skach, 2011). Less is known about the assisted folding in 63 
the ER membrane and on the cytosolic side. If folding or assembly in any of these 64 
environments fails, the protein is recognized by quality control machineries and targeted to the 65 
ER associated degradation (ERAD) pathway (Lemus and Goder, 2014). ERAD involves 66 
polyubiquitination of the cytosolic domains of transmembrane protein, extraction from the ER 67 
membrane and degradation by the proteasome (Lemus and Goder, 2014). 68 
Here we have studied the biogenesis of Low-density lipoprotein Receptor-related Protein 6 69 
(LRP6), a key component of the canonical Wnt signaling pathway, which has been associated 70 
with many human pathologies including cancer, osteoporosis and metabolic diseases (Joiner et 71 
al., 2013), but also involved in the formation of gap junctions in cardiomyocytes (Li et al., 72 
2016). LRP6 is a type I membrane protein composed of a large extracellular domain 73 
containing multiple ß-propeller and EGF-like domains (MacDonald et al., 2009). Proper 74 
folding of the ß-propeller domains depends of the dedicated LRP6 chaperone Mesd 75 
(mesoderm development) (Hsieh et al., 2003) and possibly other chaperones such as calnexin. 76 
We have previously shown that exit of LRP6 from the ER also requires a cytoplasmic post-77 
translational modification, namely S-palmitoylation, on two cysteine residues in close 78 
proximity to the transmembrane domain (Abrami et al., 2008b). LRP6 acylation influences the 79 
conformation of this domain, possibly by alleviating the hydrophobic mismatch between the 80 
thickness of the membrane and the length of the hydrophobic stretch composing the 81 
transmembrane domain. Mutation of the palmitoylation sites leads to retention of LRP6 in the 82 
ER and ubiquitination on Lys-1403 (Abrami et al., 2008b) indicative of its recognition by a 83 
quality control mechanism (Feldman and van der Goot, 2009). Once properly folded, LRP6 84 
exits the ER, it transits through the Golgi, as indicated by the acquisition of Endoglycosidase 85 
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H insensitive complex sugars (Abrami et al., 2008b), before reaching the plasma membrane 86 
where its signal role takes place. 87 
Here we have further investigated LRP6 biogenesis in the ER. We show that newly 88 
synthesized wild type LRP6 also undergoes ubiquitination, on the same site (Lys-1403), and 89 
that this post-translational modification promotes its folding. For ER exit to occur, 90 
ubiquitination must however be subsequently removed. This is mediated by the 91 
deubiquitinating enzyme USP19, one of the isoforms of which is tail-anchored to the ER 92 
(Hassink et al., 2009; Wing, 2016). It is thought to play an essential role in skeletal muscle 93 
atrophy through unclear mechanisms (Wing, 2016). At the more mechanistic level, USP19 has 94 
been shown to control the stability of several cytoplasmic proteins such as the inhibitors of 95 
apoptosis c-IAP1, and c-IAP2 (Mei et al., 2011), hypoxia-inducible factor 1-alpha (HIF-1α) 96 
(Altun et al., 2012) and the initiator of autophagy Beclin1 (Jin et al., 2016). Interestingly, 97 
USP19 is a target gene of the unfolded protein response (UPR) and was found to rescue CFTR 98 
ΔF508 from ERAD (Hassink et al., 2009). More recently it was found that USP19 is a key 99 
player in a novel misfolded-protein associated secretion MAPS pathway (Lee et al., 2016). We 100 
show that USP19 controls the cellular levels of LRP6. In the absence of USP19, LRP6 is 101 
efficiently targeted to ERAD. Upon USP19 overexpression, ER exit of LRP6 is greatly 102 
enhanced.  103 
This work reveals the existence of a novel assisted-folding system that operates on the 104 
cytosolic side of the ER and depends on site-specific cycles of ubiquitination-deubiquitination. 105 
Upon ubiquitination on Lys-1403, LRP6 presumably interacts with an ubiquitin-binding 106 
protein that acts as a chaperone and provides the protein with time to fold. If folding is 107 
successful, LRP6 is transported out of the ER, a step that is favored by palmitoylation (Abrami 108 
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et al., 2008b). If folding is impaired or delayed, polyubiquitination of other cytosolic lysine 109 
residues takes over and targets LRP6 to ERAD. The here identified ubiquitination-110 
deubiquitination assisted-folding cycle also appears to operate on other membrane proteins 111 
such as CFTR or the anthrax toxin receptor 2 (also know as Capillary Morphogenesis gene 2, 112 
CMG2), loss of function of which leads to Hyaline Fibromatosis Syndrome (Deuquet et al., 113 
2011b). 114 
 115 
RESULTS AND DISCUSSION 116 
Massive degradation of newly synthesized LRP6 in the ER 117 
We analyzed LRP6 stability by performing a cycloheximide chase, which consists in 118 
following total protein expression levels by western blot analysis of extracts from Pigmented 119 
epithelial (RPE1)  cells submitted for various times to a protein synthesis block. No significant 120 
decay of LRP6 was observed over a 6hrs period (fig. 1AB). We next measured LRP6 stability 121 
by performing 35S Cys/Met metabolic pulse-chase experiments. Protein decay, monitored 122 
following a 20 min metabolic pulse, indicated that the apparent half-life (ݐభ
మ
௔௣௣) of endogenous 123 
LRP6 in RPE1 cells is approximately 3 hrs (Fig. 1CD, and supplementary information in 124 
(Abrami et al., 2008b)). The same experiment was repeated on transiently expressed myc-125 
LRP6 in HeLa cells (Fig. 1-figure supplement 1). Then, we show that ݐభ
మ
௔௣௣ was identical for 126 
endogenous LRP6 in RPE1 cells and transiently expressed myc-LRP6 in Hela, indicating that 127 
the potential difference in expression in these two systems does not affect degradation rates 128 
and allowing us to use both systems. 129 
The above apparent discrepancy between the cycloheximide chase and the metabolic labeling 130 
approach is due to the fact that stability of mature LRP6 is monitored through the first 131 
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approach, while newly synthesized LRP6 is monitored by the second. Considering the events 132 
that occur following synthesis of a membrane protein –more or less efficient folding, ER exit, 133 
transport to destination–, the ݐభ
మ
௔௣௣  of a protein determined using metabolic pulse-chase 134 
experiments may greatly dependent on the duration of the pulse. Indeed, the ݐభ
మ
௔௣௣ of LRP6 135 
increased to ≈ 5hrs for a 2 hrs pulse and >15 hrs for a 16 hrs pulse (Fig. 1CDE). The long 136 
apparent half-lives estimated both by long metabolic labeling and cycloheximide chase 137 
suggest that mature LRP6 has a half-life that exceeds 20 hrs. The rapid decay times observed 138 
for short metabolic pulses on the other hand indicate that close to 80% of newly synthesized 139 
LRP6 molecules are degraded in our cells within the first 6 hrs (Fig. 1D), and thus do not 140 
contribute to the population of active Wnt signaling co-receptors.  141 
Cellular degradation of membrane proteins can occur by two main pathways: ERAD, where 142 
proteolysis is mediated by the proteasome, or the lysosomal pathway, which is responsible for 143 
degradation of most membrane proteins but is also the endpoint of autophagy (Fig. 1I). To 144 
determine the relative contribution of these pathways to the degradation of LRP6, we repeated 145 
the 20 min metabolic pulse-chase experiments while either inhibiting the proteasome with 146 
MG132 or preventing lysosomal degradation by inhibiting the vacuolar ATPase with 147 
Bafilomycin A. MG132 protected LRP6 from degradation early after synthesis (Fig. 1FG), 148 
consistent with degradation of a subpopulation of LRP6 molecules by ERAD during 149 
biogenesis. Bafilomycin A protected LRP6 at later times (Fig. 1FG), consistent with transport 150 
of a portion of newly synthesized LRP6 molecules to the plasma membrane and their 151 
subsequent endocytosis and targeting to lysosomes (Fig. 1I). That LRP6 undergoes 152 
degradation by two distinct pathways is further support by the observation that palmitoylation 153 
deficient LRP6, in which the two cysteines are mutated to serines (LRP6େେିୗୗ), and which 154 
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does not exit the ER (Abrami et al., 2008b), is partially rescued by MG132 (Fig. 1H) but is 155 
insensitive to inhibitors of lysosomal enzymes such as Bafilomycin A (Fig. 1H) or leupeptin 156 
(supplementary information in (Abrami et al., 2008b)). The involvement of lysosomal 157 
enzymes in LRP6 degradation thus requires export out of the ER. 158 
 159 
Role of palmitoylation and ubiquitination in LRP6 biogenesis 160 
We have previously shown that LRP6 undergoes palmitoylation in the ER on Cys-1394 and 161 
Cys-1399 and that palmitoylation is required for ER exit (Abrami et al., 2008b). This was 162 
based on the observation that palmitoylation deficient LRP6 did not exit the ER and 163 
underwent ubiquitination on Lys-1403 (Abrami et al., 2008b). To further investigate the 164 
importance of palmitoylation and ubiquitination on LRP6 biogenesis, we performed 35S 165 
Cys/Met metabolic pulse-chase experiments on the palmitoylation deficient LRP6େେିୗୗ 166 
mutant, on the K1403R mutant ( LRP6୏ଵସ଴ଷୖ ) and on the triple mutant ( LRP6୏ଵସ଴ଷୖେେିୗୗ ). 167 
Following a 20 min pulse, no significant difference in degradation was observed between wild 168 
type LRP6 and LRP6େେିୗୗ (Fig. 2A) in agreement with our previous observations (Abrami et 169 
al., 2008b). In contrast, degradation was accelerated by the K1403R mutation (Fig. 2A).  170 
To estimate the importance of the contribution of Lys-1403 to LRP6 folding, we compared the 171 
effect of this mutation to that of silencing the dedicated LRP6 chaperone Mesd. Remarkably, 172 
mutation of Lys-1403 had a more pronounced effect on LRP6 degradation than mesd silencing 173 
(Fig. 2B). Accelerated LRP6୏ଵସ଴ଷୖ degradation did not involve lysosomes since Bafilomycin 174 
A had no effect, also suggesting that newly synthesized LRP6୏ଵସ଴ଷୖ does not significantly exit 175 
the ER during the 6 hrs that follow its synthesis. Degradation of LRP6୏ଵସ଴ଷୖ could however 176 
be partially rescued by MG132 (Fig. 2C). 177 
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Consistent with its targeting to the proteasome, LRP6୏ଵସ଴ଷୖunderwent polyubiquitination as 178 
revealed when immunoprecipitating LRP6 from MG132 treated cells and blotting against 179 
ubiquitin (Fig. 2D).  This observation also shows that ERAD targeting of LRP6 does not 180 
involve, or at least does not require, Lys-1403 polyubiquitination. 181 
Extending the pulse time to 2 or 16 hrs revealed that the stability of LRP6 does depend on 182 
palmitoylation (Fig. 2EF). The tripple LRP6୏ଵସ଴ଷୖେେିୗୗ  mutant was therefore the least stable (Fig. 183 
2F).  184 
Altogether these observations indicate that spontaneous folding of LRP6 is very inefficient, 185 
and that both ubiquitination and palmitoylation promote LRP6 biogenesis and ER exit. The 186 
process is however not all-or-none, i.e. even in the absence of Lys-1403 and/or palmitoylation, 187 
a small population of molecules folds properly and exits the ER. Pulse-chase experiments with 188 
long 35S pulses indeed reveal biphasic decay curves for all mutants studied, and show the 189 
existence, irrespective of the mutations, of a minor population of extremely long-lived 190 
molecules, which presumably reside at the plasma membrane. Importantly these constitute the 191 
steady state population that is revealed by western blotting. Western blot analysis of LRP6 192 
mutants may therefore be misleading as to the importance of specific residues for biogenesis 193 
and membrane targeting (Abrami et al., 2008b). 194 
 195 
Working Hypothesis 196 
The above findings, combined with our previous observation that LRP6େେିୗୗ undergoes 197 
ubiquitination on Lys-1403 and fails to exit the ER (Abrami et al., 2008b), led us to propose 198 
the following working hypothesis: following synthesis and insertion into the ER membrane, 199 
LRP6 first undergoes ubiquitination, probably of a specific type, on Lys-1403, allowing it to 200 
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interact with an ER or cytosolic ubiquitin-binding protein. This interaction provides LRP6 201 
with time to fold –and as such this ubiquitin-binding protein would act as a chaperone– 202 
protecting it from ERAD targeting. Lys-1403 is then deubiquitinated. At this stage, LRP6 can 203 
either 1) undergo palmitoylation of its two juxtamembranous cysteine residues, followed by 204 
ER exit, 2) be re-ubiquitinated on Lys-1403, or 3) be polyubiquitinated on one of the other 16 205 
cytoplasmic lysine residues and sent to ERAD. Option 1, re-ubiquitination on Lys-1403, 206 
allows LRP6 to undergo a second cycle of interaction with its ubiquitin-binding chaperone, 207 
further promoting folding. Palmitoylation, which favors ER exit (Abrami et al., 2008b), could 208 
prevent LRP6 from Lys-1403 ubiquitination, possibly through a conformational change of 209 
steric hindrance given the juxtamembrane localization of both modifications. 210 
A major prediction of this model is the existence of an ER localized deubiquitinating (DUB) 211 
enzyme that can remove ubiquitin specifically from Lys-1403. This DUB would control LRP6 212 
biogenesis.  213 
 214 
USP19 promotes LRP6 biogenesis and controls Wnt signaling 215 
The human genome encodes some 100 DUBs (Clague et al., 2013). Of these, the ubiquitin-216 
specific proteases (USPs) represent the largest family with 56 members (Ye, 2006). Because 217 
LRP6 folding takes place in the ER, we searched for ER-associated DUBs and to the best of 218 
our knowledge, only USP19 has an ER localized isoform (Clague et al., 2013; Hassink et al., 219 
2009; Wing, 2016). Endogenous LRP6 and USP19 could be co-immunoprecipitated from 220 
RPE1 cells (Fig. 3A). While ubiquitination of LRP6 is undetectable under control condition 221 
(Fig. 3A; see also (Abrami et al., 2008b)), silencing of usp19 (Fig. 3-figure supplement 1A) 222 
revealed a clear LRP6 ubiquitination signal (Fig. 3A), often, but not always, appearing as a 223 
well identifiable band and a smear. Strikingly, LRP6 levels dropped drastically upon usp19 224 
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silencing whether in HeLa (Fig. 3-figure supplement 1B), RPE1 cells or primary human 225 
fibroblasts (Fig. 3B and Fig. 3-figure supplement 1C). The same was observed upon 226 
CRISPR/Cas9-mediated usp19 knockout in RPE1 cells (Fig. 1-figure supplement 1B). 227 
Silencing of usp19 also led to an increase in ubiquitination of palmitoylation-deficient 228 
LRP6େେିୗୗ and a decrease of its expression  (Fig. 3-figure supplement 1D). In reverse, over 229 
expression of wild type USP19, but not of its catalytically inactive mutant (USP19C506S 230 
(Hassink et al., 2009)) reduced ubiquitination of LRP6େେିୗୗ  (Fig. 3-figure supplement 1E), 231 
indicating that USP19 influences LRP6 ubiquitination in a manner that depends on its DUB 232 
activity. Thus consistent with our working hypothesis, an ER-localized DUB, USP19, controls 233 
the expression of LRP6.  234 
We next investigated whether USP19 indeed affects LRP6 biogenesis. siRNA-mediated 235 
silencing of usp19 in HeLa cells and usp19 knock-out in RPE1 cells (Figure 1-figure 236 
supplement 1B) both led to a strong decrease in ݐభ
మ
௔௣௣ of LRP6, droping from 3 to 1 h, as 237 
monitored by 35S Cys/Met metabolic pulse-chase experiments (Fig. 3C and Figure 1-figure 238 
supplement 1A). Overexpression of wild type USP19 led to a marked increase in ݐభ
మ
௔௣௣  to 239 
above 6 hrs, beyond the time frame of these experiments. Importantly, overexpression of 240 
catalytically inactive USP19C506S had no effect. This not only shows that the catalytic activity 241 
of USP19 is required, but the complete absence of rescue also indicates that USP19 does not 242 
act as a chaperone, as proposed for the unconventional misfolded protein-associated secretion 243 
MAPS pathway (Lee et al., 2016).  244 
The palmitoylation deficient LRP6େେିୗୗ  was affected in a qualitatively similar manner: 245 
silencing usp19 decreased ݐభ
మ
௔௣௣ to less than 1 hr, while over expression of USP19 increased 246 
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ݐభ
మ
௔௣௣  to 6 hrs (Fig. 3D). Remarkably, silencing or overexpression of USP19 had no effect 247 
whatsoever on LRP6௄ଵସ଴ଷோ (Fig. 3E). Mutation of Lys-1403 similarly abolished the regulatory 248 
effect of USP19 on LRP6େେିୗୗ, ܮܴܲ6௄ଵସ଴ଷோ஼஼ିௌௌ  being insensitive to the cellular USP19 levels 249 
(Fig. 3F). Altogether these experiments clearly point to Lys-1403 as the specific target site of 250 
USP19, revealing the crucial role of this residue in preventing early LRP6 degradation. These 251 
experiments also show that USP19, even when overexpressed, cannot reverse the 252 
polyubiquination undergone by ܮܴܲ6௄ଵସ଴ଷோ  and thus ERAD targeting, further highlighting 253 
the specificity of this DUB. Finally, these observations demonstrate that USP19 promotes the 254 
biogenesis of LRP6, with only 18% of newly synthesized LRP6 molecules surviving beyond 6 255 
hrs in the absence of USP19 and 60% surviving upon USP19 overexpression.  256 
We finally tested the importance of USP19 for LRP6 function, as the co-receptor in Wnt 257 
signaling. Overexpression of USP19 in HeLa cells lead to a 50% increase in the Wnt signaling 258 
capacity (Fig. 4A), monitored using the TOPFLASH reporter assay (Abrami et al., 2008a). 259 
Most strikingly, silencing of usp19, but not usp13, in RPE1 cells stably expressing 7xTCF-260 
FFluc directly activated by the TCF/-βcatenin complex led to a more than 80% drop in Wnt 261 
signaling (Fig. 4B). In agreement, surface biotinylation showed that usp19 silencing lead to a 262 
drastic drop LRP6 at the cell surface (Fig. 4-figure supplement 1).  263 
 264 
Concluding remarks 265 
We here reveal the existence of an ubiquitin-dependent folding machinery, which operates on 266 
the cytosolic side of the ER membrane (Fig. 4C). More specifically we show that following 267 
synthesis, LRP6 undergoes ubiquitination on Lys-1403, most likely of a specific form. In 268 
conceptual analogy to the binding of newly synthesized mono-glucosylated proteins to 269 
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calnexin in the ER lumen (Lamriben et al., 2016), we hypothesize that Lys-1403-ubiquitin can 270 
interact with a putative ER-ubiquitin binding protein that would also act as a chaperone. Upon 271 
release from this putative ubiquitin-binding chaperone, LRP6 is deubiquitinated by USP19. 272 
Following USP19 deubiquitination, LRP6 can, if properly folded, exit the ER, an events 273 
possibly promoted by palmitoylation of cysteines in the vicinity of Lys-1403 (Abrami et al., 274 
2008b). Or, LRP6 can undergo a new cycle of Lys-1403-specific ubiquitination and chaperone 275 
binding. Upon prolonged presence in the ER, LRP6 undergoes polyubiquitination on other 276 
cytosolic lysines, leading to ERAD targeting. In the ER, LRP6 can thus undergo two types of 277 
ubiquitination events, which operate with different kinetics: 1) specific ubiquitination on Lys-278 
1403 which promotes folding, 2) the slower polyubiquitination on other lysines which 279 
promotes ERAD. These two types of ubiquitination events are reminiscent of de-glucosidation 280 
and de-mannosidation of glycoproteins in the ER lumen, which also occur with different 281 
kinetics. De-glucosidation promotes folding of glycosylated protein, but if folding is too 282 
lengthy or fails, de-mannosidation takes place and targets the protein to ERAD. 283 
While the here described ubiquitin-dependent folding system was identified for LRP6, it likely 284 
also operates on other membrane proteins. We indeed found that usp19 silencing also led to a 285 
pronounced decrease in the levels of CMG2 (Fig 4D), defective folding of which lead to 286 
Hyaline Fibromatosis Syndrome (OMIM #228600) (Deuquet et al., 2009; Deuquet et al., 287 
2011a). Silencing of usp19 however did not affect the levels of the CMG2-related protein 288 
TEM8 (Tumor endothelial marker 8), nor those of the Transferrin and the EGF receptors (Fig 289 
4D). USP19 was reported to rescue the CFTR Δ508 mutant, which is an ERAD substrate 290 
(Hassink et al., 2009). USP19 however also controls proteostasis of wild type CFTR (Fig 4E). 291 
Future studies are required to establish the generality of this ubiquitin-dependent folding 292 
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system, determine whether it has a built-in quality control, and identify the missing 293 
components such as the folding-promoting ubiquitin ligase, the putative ubiquitin-binding 294 
chaperone and the degradation-targeting ligase (Fig. 4C). All these enzymes could be 295 
exploited to control Wnt signaling in the context of disease. 296 
 297 
MATERIAL AND METHODS 298 
Cell Lines and Cell Culture 299 
Hela and RPE1 cells were used in this study. These cells are not on the list of commonly 300 
misidentified cell lines maintained by the International Cell Line Authentication Committee . 301 
They were mycoplasma negative as tested on a trimestral basis using the MycoProbe 302 
Mycoplasma Detection Kit   CUL001B. RPE1 cells were maintained in DMEM high glucose 303 
supplemented with 10% Fetal Calf Serum, 2mM penicillin and Streptomycin and HeLa cells 304 
were maintained in MEM supplemented with 10% FCS, 2mM L-Glutamine and antibiotics. 305 
RPE1 USP19 knockout cell lines were generated using the CRISPR/Cas9 technology. Briefly, 306 
the cells were co-transfected with three plasmids: MLML3636, JDS246 carrying the gRNA 307 
sequence TCTGGCGGGGCCAGTGCCAC and GFP encoding plasmid. Single GFP 308 
transfected cells were sorted by FACS in 96 well plates. The Knockout clones were detected 309 
by western blot (Fig. S1B). 310 
 311 
Antibodies and Reagents 312 
We used the following primary antibodies: Rabbit anti-LRP6 mAb (Cell Signaling, #2560 313 
RRID:AB_2139329), Mouse anti-Actin mAb (Millipore, MAB1510), Mouse anti-Myc 9E10 314 
mAb (Covance MMS-150R RRID:AB_291327), Mouse Ubiquitin (Santa Cruz sc-8017 315 
RRID:AB_628423), Goat anti-CMG2 (R&D systems #AF2940), TEM8 (Sigma 316 
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SAB2501028), Mouse anti-Tf-R (Zymed, #13-6800), Mouse anti-EGF-R (Sigma E3138, 317 
RRID:AB_476925), CFTR (home-made), Mouse anti-Tubulin (Sigma T5168), Mouse anti-318 
GFP (Roche, #11814460001), Rabbit anti-USP19 (Bethyl, A301-587A, RRID:AB_1078839). 319 
We used the following beads for immunoprecipitations: Protein G Sepharose 4 Fast Flow (GE 320 
Healthcare, 17-0618-01), Streptavidin Agarose (Sigma, S1638), anti-Myc Affinity Gel 321 
(Thermo Scientific # 20169). 322 
 323 
Plasmids and Transfections 324 
LRP6 encoding plasmids as been previously described (Abrami et al., 2008b). The 325 
catalytically inactive mutant was obtained by Quik Change Technology (Agilent) according to 326 
manufacturer’s instruction. Plasmids were transfected into RPE1 and HeLa cells for 24h in 327 
cDNA/9.6cm2 plate using Fugene (Roche Diagnostics). For the dual Luciferase assay, 328 
plasmids and reagents were from Promega.  329 
 330 
Biochemical assays 331 
For immunoprecipitation, cells were PBS washed and lysed 30min at 4°C in IP Buffer (0.5% 332 
Nonidet P-40, 500 mM Tris pH 7.4, 20 mM EDTA, 10 mM NaF, 2 mM benzamidin and 333 
protease inhibitor cocktail (Roche), and centrifuged 3-5 min at 5000 rpm. Supernatants were 334 
incubated overnight with Sepharose beads. In case of non-coupled Sepharose G beads, 335 
supernatants were subjected to preclearing with the beads prior to the actual 336 
immunoprecipitation reaction.  337 
Cell surface protein biotinylation was performed as described (Abrami et al., 2008b). Briefly, 338 
silenced cells were treated 30 min with 0.17 mg/ml sulfo-NHS-Biotin (Pierce) at 4°C, 339 
quenched with 100mM NH4Cl, and lysed in IP Buffer (as described above). The lysate was 340 
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immunoprecipitated with streptavidin-coated sepharose beads (Sigma, S1638). 341 
The dual luciferase assays were performed with plasmids and reagents from Promega. 342 
HEK293 cells were transfected with 0.1ug TOP-Luciferase, 50 ng TK-Renilla, 0.25ug Mesd 343 
encoding plasmid and 0.5 ug myc-LRP6 wild type or mutant encoding plasmids /9.6 cm2 344 
plate. The cells were lysed 24h after transfection and the luciferase activity was determined 345 
according to the manufacturer’s instructions. 346 
The drugs are used in complete medium at the final concentration of 10 μM for MG132 and 347 
100 nM for Bafilomycin A 2 hrs before the starvation and are kept during the whole 348 
experiment. 349 
 350 
Metabolic and cycloheximide chases 351 
For the metabolic chases, the cells were starved in DMEM HG devoid of Cys/Met for 40 352 
minutes at 37°C, pulsed with the same medium supplemented with 140 μCi of 35S Cys/Met for 353 
the indicated time, washed and incubated in DMEM complete medium for the indicated time 354 
of chase (Abrami et al., 2008). 355 
For the cycloheximide chases, the cells were incubated in medium supplemented with 356 
10µg/ml of cycloheximide for 2 hours, washed and incubated in complete medium for the 357 
indicated time.  358 
 359 
  360 
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FIGURE LEGENDS 376 
Figure 1: LRP6 undergoes rapid degradation following synthesis in the ER but is stable 377 
once mature. A:  representative western blot of a cycloheximide (CHX) chase in RPE1 cells. 378 
40  µg of total cell extracts from RPE1 cells were loaded per lane, analyzed by SDS-PAGE 379 
followed by Western blotting against endogenous LRP6, calnexin (Calx), a stable protein and 380 
Myc, a short lived protein. B: Experiments as in A were quantified by ImageJ software, n=3. 381 
CDE: RPE1 cells were submitted to metabolic 35S Cys/Met labeling for different times and 382 
subsequently chased for different times. Endogenous LRP6 was immunoprecipitated with an 383 
anti-LRP6 antibody. A representative experiment in shown in C. Autoradiograms were 384 
quantified using the Typhoon imager and means of different experiments were calculated (D 385 
and E). Error bars represent standard deviation (n=6 for the 20 min pulse; n=4 for the 2 hrs 386 
and 16 hrs pulses). FG: RPE1 cells were treated or not with MG132 or Bafilomycin A and 387 
subsequently submitted, in the presence or not of the drugs, to metabolic a 20 min 35S-388 
Cys/Met pulse followed by different chase times. A representative experiment in shown in F. 389 
Errors represent standard deviation (n=4 for MG132; n=3 for Bafilomycin A, BafA, the WT 390 
control curve corresponds to that shown in Fig. 1D). G: Hela cells transiently expressing myc-391 
tagged palmitoylation deficient LRP6 (CC-SS) were submitted to metabolic 35S Cys/Met 392 
labeling for different times and subsequently chased for different times. LRP6 was 393 
subsequently immunoprecipitated using an anti-myc antibody. Errors represent standard 394 
deviation (n=3). H: Cartoon depicting the two major cellular degradation pathways for 395 
membrane proteins: ERAD (blocked by MG132) and lysosomal pathway (blocked by 396 
Bafilomycin A).  397 
 398 
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Figure 2: Mutation of the palmitoylation sites and the Lys-1403 ubiquitination site 399 
accelerate LRP6 targeting to ERAD. A: Metabolic 35SCys/Met pulse chase experiment (20 400 
minutes pulse) on transiently expressed myc-LRP6 wild type (WT, curve corresponding to the 401 
one in Fig. 1D), palmitoylation deficient (CC-SS, n=3) or K1403R (KR, n=6) mutants in HeLa 402 
cells. B: Metabolic 35SCys/Met pulse chase experiment (20 minutes pulse) on transiently 403 
expressed myc-LRP6 wild type (WT, n=7), or K1403R (K1403R, n=7) mutant in HeLa cells 404 
silenced or not for mesd gene (siRNA mesd, n=3). Errors represent standard 405 
deviation,*<p=0.05 calculated between LRP6 WT and K1403R. C: Metabolic 35SCys/Met 406 
pulse chase experiment (20 minutes pulse) on transiently expressed myc-LRP6K1403R in 407 
HeLa cells supplemented or not (n= 6, curve corresponding to the one in Fig. 2A) with 408 
MG132 (K1403 + MG123, n=3) or Bafilomycin A (K1403 + BafA, n=3). D: 409 
Immunoprecipitation of myc-tagged LRP6 Wild Type (WT) and K1403 mutant (KR) revealed 410 
with anti-Ubiquitin antibody, with or without MG132 treatment. E: Metabolic 35SCys/Met 411 
pulse chase experiment (2 hrs pulse) on transiently expressed myc-LRP6 wild type (WT, n=4, 412 
curve corresponding to the one in Fig. 1D) or palmitoylation deficient (CC-SS, n=3) in HeLa 413 
cells. F: Metabolic 35SCys/Met pulse chase experiment (16h pulse) on transiently expressed 414 
myc-LRP6 wild type (WT, curve corresponding to the one in Fig. 1D), palmitoylation 415 
deficient (CC-SS, n=3), K1403R (K1403R, n=3) or K1403R in the palmitoyl deficient 416 
background (CC-SS + KR, n=3) mutants in HeLa cells. 417 
 418 
Figure 3: De-ubiquitination of LRP6 by USP19 on Lys-1403 promotes LRP6 biogenesis. 419 
A: Immunoprecipitation of endogenous LRP6 and B: cellular level in RPE1 cells upon usp19 420 
silencing. C/D/E/F: Metabolic 35SCys/Met pulse chase experiment (20 minutes pulse) on 421 
transiently expressed myc-LRP6 wild type (WT), palmitoylation deficient mutant (CC-SS), 422 
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K1403R mutant (K1403R) or K1403R mutation in the palmitoyl deficient background (CC-SS 423 
+ KR) mutants in HeLa cells upon over expression of GFP-tagged USP19 (O.E. USP19) or 424 
GFP-tagged USP19 catalytically inactive (O.E. USP19 C-S) or upon usp19 gene silencing 425 
(siRNA USP19). C: WT n=6, same as in Fig. 1D, other conditions n=3, D (CC-SS curve 426 
corresponding to the one in figure 2A) and F: all conditions n=3, E: K1403R n=6, other 427 
conditions n=3.  428 
 429 
Figure 4: USP19 controls the Wnt signaling capacity of the cell. A: Wnt signaling 430 
measured in HEK293 cells carrying the TOPFLASH reporter assay, transiently transfected for 431 
the indicated constructs (n=5) B: Wnt signaling measured in RPE1 cells stably expressing 432 
lentiviral vector possessing a 7xTCF-FFluc upon usp19 or usp13 silencing (n=4). C: Working 433 
model (described in the text). D: cellular level of the indicated endogenous proteins in RPE1 434 
cells upon usp19 silencing (siRNA) or overexpression (O.E.) of GFP-tagged USP19. E: 435 
cellular level of transiently co-transfected CFTR (constant amount) and GFP-tagged USP19 436 
(increasing amount) in RPE1 cells.  437 
  438 
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FIGURE SUPPLEMENT LEGENDS 439 
Figure 1-figure supplement 1: Variation in USP19 cellular amount influences LRP6 440 
degradation rates. A: Metabolic 35SCys/Met pulse chase experiment (20 minutes pulse) in 441 
the following conditions: immunoprecipitation of myc-LPR6 in HeLa cells transiently 442 
expressing myc-LRP6 wild type (WT) upon control silencing (HeLa si Ctrl, n=7) vs. usp19 443 
silencing (HeLa + siRNA USP19, n=6) or upon co-overexpression of myc-LRP6 wild type 444 
and wild type GFP-tagged USP19 (HeLa + OE USP19 WT, n=6) vs. catalytically inactive 445 
GFP-tagged USP19 (HeLa + O.E. USP19 CS, n=6); immunoprecipitation of endogenous 446 
LRP6 in RPE1 cells wild type (RPE1, n=4) vs. RPE1 knout-out cells for usp19 gene (RPE1 447 
delta USP19, n=3). B: Total cell extract of wild type RPE1 and RPE1 knout-out cells for 448 
usp19 gene revealed with USP19, LRP6 and Actin antibodies. 449 
 450 
Figure 3-figure supplement 1: Variation in USP19 cellular amount influences LRP6 451 
ubiquitination state. A: RT-PCR detecting usp19, usp13 and LRP6 mRNA expression level 452 
upon silencing of usp19 and usp13 genes with specific RNAi. Errors represent standard 453 
deviation. B: Total cell extracts of Hela transiently expressing Myc-LRP6 and silenced with 3 454 
different RNAi targeting usp19 gene. C: Total cell extract of primary fibroblasts silenced for 455 
usp19 gene or overexpressing GFP-tagged USP19 revealed with GFP, LRP6 and Actin 456 
antibodies. Quantification of LRP6 cellular amount is shown on the right. Errors represent 457 
standard deviation (n=3) and *<p=0.05. C: Immunoprecipitation of transiently expressed 458 
palmitoylation deficient myc-LRP6 (Myc-LRP6CC-SS) upon usp19 silencing. Quantification of 459 
Myc-LRP6CC-SS cellular amount in TCE is shown on the right. Errors represent standard 460 
deviation (n=3) and *<p=0.05. D: Immunoprecipitation of transiently expressed 461 
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palmitoylation deficient myc-LRP6 (Myc-LRP6CC-SS) upon overexpression of GFP-tagged 462 
USP19 vs. GFP-tagged USP19 (GFP-USP19) catalytically inactive mutant (GFP-USP19C506S). 463 
 464 
Figure 4-figure supplement 1: usp19 silencing leads to decrease in LRP6 cell surface 465 
expression. Surface Biotinylation assay performed in RPE1 cells upon 24, 48 and 72 hrs of 466 
usp19 or usp13 gene silencing. Quantification of endogenous LRP6 surface expression at 48 467 
hrs of gene silencing in Streptavidin-mediated pull down is shown above the western blot. 468 
Errors represent standard deviation (n=3) and ***<p=0.0005. 469 
 470 
Figure 1-source data 1: numeric data for graphs of figure 1B, 1D, 1E, 1F, and 1H 471 
 472 
Figure 2-source data 2: numeric data for graphs of figure 2A, 2B, 2C, 2E and 2F 473 
 474 
Figure 3-source data 3: numeric data for graphs of figure 3C, 3D, 3E and 3F 475 
 476 
Figure 4-source data 4: numeric data for graphs of figure 4A and 4B 477 
 478 
Figure 1-suppl1-source data 1: numeric data for graphs of figure 1 S1A 479 
 480 
Figure 3-suppl1-source data 1: numeric data for graphs of figure 3 S1A and 3 S1C 481 
 482 
Figure 4-suppl1-source data 1: numeric data for graphs of figure 4 S1 483 
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